Merz licenses TAU Alzheimer's drug

Merz is the developer of Memantine, an anti-dementia drug, as well as treatments for Parkinson's Disease and depression.

By YONI TEITZ
July 11, 2007 08:37

Tel Aviv University has licensed an Alzheimer's treatment it developed to Merz Pharmaceuticals, a German producer of Alzheimer's drugs. Ramot, Tel Aviv University's technology transfer company, raised $8.5 million for research into the treatment in 2003. Merz is the developer of Memantine, an anti-dementia drug, as well as treatments for Parkinson's Disease and depression.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Cookie Settings